>Marché des dispositifs de neurostimulation interne en Amérique du Nord, par type de produit ( stimulation de la moelle épinière (SCS), stimulation cérébrale profonde , stimulation du nerf vague, stimulation du nerf sacré et stimulation électrique gastrique ), canal de distribution (appel d'offres direct et fournisseur de services tiers) - Tendances et prévisions de l'industrie jusqu'en 2029.
Analyse et perspectives du marché des dispositifs de neurostimulation interne en Amérique du Nord
L'augmentation de la demande d'appareils de neurostimulation interne en tant que thérapie complémentaire, l'augmentation de la prévalence et de l'incidence des maladies neurologiques, l'augmentation du financement des appareils de neurostimulation, les avancées technologiques dans les appareils de neurostimulation interne et l'augmentation des approbations de produits devraient stimuler la croissance du marché.
Les initiatives stratégiques des acteurs du marché et l'augmentation du financement des acteurs publics et privés du marché des dispositifs de neurostimulation interne devraient créer des opportunités de croissance du marché. Cependant, le manque d'experts qualifiés et formés dans le domaine des dispositifs de neurostimulation interne devrait freiner la croissance du segment. La disponibilité d'autres dispositifs d'imagerie devrait remettre en cause la croissance du marché.
Data Bridge Market Research analyse que le marché nord-américain des dispositifs de neurostimulation interne croîtra à un TCAC de 20,5 % et 9 898,11 millions USD au cours de la période de prévision de 2022 à 2029.
|
Rapport métrique |
Détails |
|
Période de prévision |
2022 à 2029 |
|
Année de base |
2021 |
|
Années historiques |
2020 (personnalisable de 2019 à 2024) |
|
Unités quantitatives |
Chiffre d'affaires en millions USD, prix en USD |
|
Segments couverts |
Par type de produit ( stimulation de la moelle épinière (SCS), stimulation cérébrale profonde, stimulation du nerf vague, stimulation du nerf sacré et stimulation électrique gastrique ), canal de distribution (appel d'offres direct et fournisseur de services tiers) |
|
Pays couverts |
États-Unis, Canada et Mexique |
|
Acteurs du marché couverts |
Medtronic, LivaNova PLC, Abbott, ONWARD, Sequana Medical NV, CIRTEC, Valencia Technologies, Nalu Medical, Inc., NEVRO CORP., Stimwave LLC, MicroTransponder Inc., Newronika SpA, Microsemi (une filiale de Microchip Technology Inc.), Boston Scientific Corporation, Inspire Medical Systems, Inc, Integer Holdings Corporation, BlueWind Medical, Micro-Leads, Axonics, Inc., entre autres |
Définition du marché
Un dispositif de neurostimulation interne est un dispositif placé chirurgicalement. Il délivre de légers signaux électriques à l'espace épidural près de votre colonne vertébrale via un ou plusieurs fils fins appelés sondes. La neurostimulation soulage la douleur en perturbant les signaux de douleur circulant entre la moelle épinière et le cerveau.
Neurostimulation devices include invasive and noninvasive approaches involving electrical stimulation to drive neural function within a circuit. The increased demand for internal neurostimulation devices is due to next-generation technological progressions in the neurostimulation devices, providing much-needed therapeutic relief to an unprecedented number of people affected by debilitating neurologic and psychiatric disorders worldwide. The rise of modern-day neuromodulation therapies has increased over half a century, rich with serendipitous discoveries and technological advances that have led to different neurostimulation strategies. Within the past two decades, innovation in medical device technology has begun to drive the evolution of these neurostimulation systems at a more accelerated pace.
The convenient internal neurostimulation device used by the patients is vagus nerve stimulation. The vagus neurostimulation device uses a device to stimulate the vagus nerve with electrical impulses. An implantable vagus nerve stimulator is currently FDA-approved to treat epilepsy and depression. There's one vagus nerve on each side of the body, running from the brainstem through the neck to the chest and abdomen. In the future, software advancements such as closed-loop stimulation and remote programming will enable internal neurostimulation devices to be a more personalized and accessible technology. The future of internal neurostimulation devices is expected to improve quality of life further.
North America Internal Neurostimulation Devices Market Dynamics
This section deals with understanding the market drivers, opportunities, restraints, and challenges. All of this is discussed in detail below:
Drivers
- Increased Awareness About Treatment of Chronic Urinary Incontinence
Increasing awareness among patients and health care providers and greater access to continence services were key factors in improving care delivery. Urinary incontinence (UI) and lower urinary tract symptoms (LUTS) are common and cause distress for many women and men of all ages. The increased awareness of implant internal neurostimulation devices in neurology signifies the increase in research and development-related investments for the discovery and development of advanced, pain-free internal neurostimulation devices, which is expected to boost market growth.
- Technological Advancements in the Internal Neurostimulation Devices
The technological developments in internal neurostimulation devices utilize neuromodulation technology, which directly delivers the electrical or pharmaceutical agents to a target area. The neuromodulation and internal neurostimulation devices and treatments are life-changing. Technological developments modulate neural functions in a programmable manner and regulate disordered neural activity. The results can be delivered with minimum error.
For instance,
- In May 2022, ONWARD introduced the ARC implantable pulse generator (IPG) to stimulate the spinal cord to restore movement and autonomic function for people with SCI and other conditions that impact mobility
The approval for the internal neurostimulation devices would result in the device being declared safe to use and ready for post-marketing approval. It would result in the supply and distribution of MRI machines to the developing markets in the U.S. demographics. Hence, the rise in product approvals is expected to propel the North America internal neurostimulation devices market growth.
Opportunities
- Recent Product Developments in the Internal Neurostimulation Devices
The growth curve for the North America internal neurostimulation devices market is following an upward trend due to the demand for effective neurovascular therapies is steadily increasing due to the increasing prevalence of neurovascular diseases (such as epilepsy, brain stroke, and cerebral aneurysm) and the severity of diseases (such as discharge and surrounding disorders) in target patients. Due to the rising prevalence and increasing awareness about the seriousness of these diseases, various equipment or devices are manufactured or are under clinical trials.
Thus, product development in recent years has shown the potential of these technologies, and the companies working in this market are trying to get more advanced products, which will act as an opportunity for market growth.
- Strategic Initiatives by the Key Market Player
The demand for internal neurostimulation devices is increasing in the market owing to the increased levels of research and development along with the growth of the North America internal neurostimulation devices market aided by the desire for innovative medications. Thus, the top market players have implemented a new strategy by developing new devices and equipment, collaborating with other players in the market, and improving business operations and profitability.
- In January 2021, Boston Scientific began shipping their Wave Writer Alpha spinal line trigger frameworks to the U.S.
Thus, the companies operating globally in the neurostimulation devices market are adopting collaboration to increase their product portfolio with advanced technology-rich products to boost their business in various dimensions. Thus, strategic initiatives by key market players are expected to offer significant opportunities for the market players operating in the North America internal neurostimulation devices market.
Restraints/Challenges
- Risks Associated with the Implantation of these Devices
Medical implants carry several hazards, including those related to surgery during installation or removal, infection, and implant failure. The materials used in implants can potentially cause responses in some persons. Every surgical procedure carries some risk. These include bruising, discomfort, swelling, and redness at the surgery site. Thereby will proportionally hamper the growth of implant devices. The increasing awareness about the rising risks related to neurostimulation implants, therefore, may hamper the market's growth.
For instance,
- Implant failure
- Surgical risks during placement or removal
- Risk of implantable device hijacking
- Rising infections
- Materials used in implants might show adverse reactions in patients
The risks mentioned above may hamper the growth of the internal neurostimulation devices market as the risks concerned with the patients are of keen importance. Thus, the awareness of the potential risks of implantable devices is a challenge for the North America internal neurostimulation devices market.
- Lack of Skilled Healthcare Professionals
Neurostimulation devices are implantable, programmable medical devices that deliver electrical stimulation to specific parts of the patient's brain, spinal cord, or peripheral nervous system to help treat various conditions, including chronic pain, movement disorders, epilepsy, and Parkinson's disease. These powerful technologies require a high-cost developmental procedure and skilled professionals to handle sensitive devices. The replacement should be done every 3-6 years after implantation, which is a cost burden and is typically out of pocket for most patients.
Only a relatively small number of patients in poorer nations can afford neurological therapy due to high prices, a weak reimbursement environment, and a lack of skilled healthcare resources. As a result, healthcare facilities are hesitant to spend money on novel or cutting-edge technology, limiting the expansion of the market. Thus, these challenges may hamper the growth of the market.
COVID-19 Impact on the North America Internal Neurostimulation Devices Market
During the pandemic, the North America Internal neurostimulation devices sector focuses on using a combination of biology and information technology. During the COVID-19 pandemic, new therapeutic challenges have been added to the usual ones in the internal neurostimulation devices. Patients with an implantable device for intrathecal infusion need a refill of the pump to avoid abstinence syndrome. Patients with neurostimulation implants can need checkups in case of infection, wound dehiscence, or lead migration.
Recent Developments
- En janvier 2022, Medtronic a reçu l'approbation de la Food and Drug Administration (FDA) pour le neurostimulateur rechargeable Intellis, une thérapie de stimulation de la moelle épinière destinée au traitement de la douleur chronique résultant de la neuropathie diabétique périphérique. L'approbation du produit reçue a donné lieu à l'ajout d'un nouveau produit dans la catégorie des produits de stimulation de la moelle épinière. L'approbation devrait être approuvée après la mise sur le marché aux États-Unis
- En juillet 2022, Abbott a reçu l'approbation de la Food and Drug Administration (FDA) pour le système de stimulation cérébrale profonde Infinity pour le traitement de la dépression. L'approbation reçue a entraîné une augmentation du nombre d'approbations avant et après commercialisation et l'ajout d'un nouveau produit au portefeuille de produits
Portée du marché des dispositifs de neurostimulation interne en Amérique du Nord
Le marché nord-américain des dispositifs de neurostimulation interne est classé en type de produit et en canal de distribution. La croissance de ces segments vous aidera à analyser les segments de faible croissance dans les industries et à fournir aux utilisateurs un aperçu précieux du marché et des informations sur le marché pour les aider à prendre des décisions stratégiques pour identifier les principales applications du marché.
Type de produit
- Stimulation de la moelle épinière (SCS)
- Stimulation cérébrale profonde
- Stimulation du nerf vague
- Stimulation du nerf sacré
- Stimulation électrique gastrique
Sur la base du type de produit, le marché nord-américain des dispositifs de neurostimulation interne est segmenté en stimulation de la moelle épinière (SCS), stimulation cérébrale profonde, stimulation du nerf vague , stimulation du nerf sacré et stimulation électrique gastrique.
Canal de distribution
- Appel d'offres direct
- Fournisseur de services tiers
Sur la base du canal de distribution, le marché nord-américain des dispositifs de neurostimulation interne est segmenté en appels d'offres directs et fournisseurs de services tiers.
Analyse/perspectives régionales du marché des dispositifs de neurostimulation interne en Amérique du Nord
Le marché des dispositifs de neurostimulation interne en Amérique du Nord est analysé et les régions fournissent des informations sur la taille du marché et les tendances par pays, type de produit et canal de distribution, comme indiqué ci-dessus.
Certains pays couverts par le marché des dispositifs de neurostimulation interne en Amérique du Nord sont les États-Unis, le Canada et le Mexique. Les États-Unis devraient dominer le marché en raison d'une augmentation des activités de recherche et développement, des exigences intégrées en matière de dispositifs de neurostimulation interne en neurologie et dans le traitement de l'incontinence urinaire, et d'une augmentation du financement des secteurs public et privé pour les dispositifs de neurostimulation.
La section pays du rapport fournit également des facteurs individuels ayant un impact sur le marché et des changements dans la réglementation du marché national qui ont un impact sur les tendances actuelles et futures du marché. Des points de données tels que les nouvelles ventes, les ventes de remplacement, la démographie du pays, l'épidémiologie des maladies et les tarifs d'importation et d'exportation sont quelques-uns des principaux indicateurs utilisés pour prévoir le scénario du marché pour les différents pays. En outre, la présence et la disponibilité des marques nord-américaines et les défis auxquels elles sont confrontées en raison de la concurrence importante ou rare des marques locales et nationales ont un impact sur les canaux de vente, sont pris en compte lors de l'analyse prévisionnelle des données nationales.
Analyse du paysage concurrentiel et des parts de marché des dispositifs de neurostimulation interne en Amérique du Nord
Le paysage concurrentiel du marché des dispositifs de neurostimulation interne en Amérique du Nord fournit des détails sur le concurrent. Les détails comprennent un aperçu de l'entreprise, les finances de l'entreprise, les revenus générés, le potentiel du marché, les investissements dans la recherche et le développement, les nouvelles initiatives du marché, la présence en Amérique du Nord, les sites et installations de production, les capacités de production, les forces et les faiblesses de l'entreprise, le lancement du produit, la largeur et l'étendue du produit et la domination des applications. Les points de données ci-dessus fournis ne concernent que l'orientation des entreprises liée au marché des dispositifs de neurostimulation interne en Amérique du Nord.
Certains des principaux acteurs opérant sur le marché des dispositifs de neurostimulation interne en Amérique du Nord sont Medtronic, LivaNova PLC, Abbott, ONWARD, Sequana Medical NV, CIRTEC, Valencia Technologies, Nalu Medical, Inc., NEVRO CORP., Stimwave LLC, MicroTransponder Inc., Newronika SpA, Microsemi (une filiale de Microchip Technology Inc.), Boston Scientific Corporation, Inspire Medical Systems, Inc, Integer Holdings Corporation, BlueWind Medical, Micro-Leads, Axonics, Inc., entre autres.
SKU-
Accédez en ligne au rapport sur le premier cloud mondial de veille économique
- Tableau de bord d'analyse de données interactif
- Tableau de bord d'analyse d'entreprise pour les opportunités à fort potentiel de croissance
- Accès d'analyste de recherche pour la personnalisation et les requêtes
- Analyse de la concurrence avec tableau de bord interactif
- Dernières actualités, mises à jour et analyse des tendances
- Exploitez la puissance de l'analyse comparative pour un suivi complet de la concurrence
Table des matières
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF NORTH AMERICA INTERNAL NEUROSTIMULATION DEVICES MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATION
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHIC SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 RESEARCH METHODOLOGY
2.6 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.7 DBMR MARKET POSITION GRID
2.8 THE CATEGORY VS TIME GRID
2.9 SECONDARY SOURCES
2.1 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL
4.2 PORTER'S FIVE FORCES MODEL
4.3 PIPELINE ANALYSIS FOR INTERNAL NEUROSTIMULATION DEVICES MARKET
5 REGULATIONS OF NORTH AMERICA INTERNAL NEUROSTIMULATION DEVICES MARKET
6 EPIDEMIOLOGY OF DISEASES
6.1 INCIDENCE OF ISCHEMIA
6.2 INCIDENCE OF PARKINSON'S DISEASE
6.3 INCIDENCE OF FAILED BACK SYNDROME
6.4 INCIDENCE OF TREMOR
6.5 INCIDENCE OF DEPRESSION
6.6 INCIDENCE OF URINE INCONTINENCE
6.7 INCIDENCE OF FECAL INCONTINENCE
6.8 INCIDENCE RATE OF EPILEPSY
6.9 INCIDENCE OF GASTROPARESIS
6.1 PREVALENCE OF OBESITY
7 EPIDEMIOLOGY OF NEUROSTIMULATION PROCEDURES
7.1 NUMBER OF SPINAL CORD STIMULATION (SCS) PROCEDURES
7.1.1 NUMBER OF TEST PROCEDURES
7.1.2 NUMBER OF IMPLANTATION PROCEDURES
7.2 NUMBER OF DEEP BRAIN STIMULATION PROCEDURES
7.3 NUMBER OF VAGUS NERVE STIMULATION PROCEDURES
7.4 NUMBER OF SACRAL NEVER STIMULATION PROCEDURES
7.5 NUMBER OF TRANSCRANIAL MAGNETIC STIMULATION (TMS) PROCEDURES
7.6 NUMBER OF INTERMITTENT THETA BURST STIMULATION (ITBS) PROCEDURES
7.7 NUMBER OF TRANSCRANIAL DIRECT ELECTRICAL STIMULATION (TDCS) PROCEDURES
8 MARKET OVERVIEW
8.1 DRIVERS
8.1.1 RISE IN PREVALENCE AND INCIDENCE OF NEUROLOGICAL DISORDERS
8.1.2 DEMAND FOR INTERNAL NEUROSTIMULATION DEVICES AS A ADD ON THERAPY
8.1.3 INCREASED FUNDING FOR THE NEUROSTIMULATION DEVICES
8.1.4 TECHNOLOGICAL ADVANCEMENTS IN THE INTERNAL NEUROSTIMULATION DEVICES
8.1.5 RISE IN PRODUCT APPROVALS
8.2 RESTRAINTS
8.2.1 RISE IN COST OF THE DEEP BRAIN STIMULATION DEVICES
8.2.2 RISKS NOTICED WHILE USING THE INTERNAL NEUROSTIMULATION DEVICES
8.2.3 RISE IN PRODUCT RECALL
8.2.4 AVAILABILITY OF ALTERNATE IMAGING DIAGNOSTIC DEVICES
8.3 OPPORTUNITIES
8.3.1 STRATEGIC INITIATIVES BY THE KEY MARKET PLAYER
8.3.2 RECENT PRODUCT DEVELOPMENTS IN THE INTERNAL NEUROSTIMULATION DEVICES
8.3.3 DEMAND FOR MINIMALLY INVASIVE SURGERY
8.4 CHALLENGES
8.4.1 RISKS ASSOCIATED WITH THE IMPLANTATION OF THESE DEVICES
8.4.2 LACK OF SKILLED HEALTHCARE PROFESSIONALS
9 NORTH AMERICA INTERNAL NEUROSTIMULATION DEVICES MARKET, BY PRODUCT TYPE
9.1 OVERVIEW
9.2 SPINAL CORD STIMULATION
9.2.1 SPINAL CORD STIMULATION, BY TYPE
9.2.1.1 BATTERY
9.2.1.1.1 RECHARGEABLE
9.2.1.1.2 NON-RECHARGEABLE
9.2.1.2 LEAD
9.2.1.2.1 PERCUTANEOUS
9.2.1.2.2 PADDLE
9.2.2 SPINAL CORD STIMULATION, BY APPLICATION
9.2.2.1 ISCHEMIA
9.2.2.2 CHRONIC LOW BACK PAIN (CLBP)
9.2.2.3 DIABETIC NEUROPATHY
9.2.2.4 FAILED BACK SYNDROME
9.3 DEEP BRAIN STIMULATION
9.3.1 DEEP BRAIN STIMULATION, BY TYPE
9.3.1.1 SINGLE CHANNEL DEEP BRAIN STIMULATOR
9.3.1.2 DOUBLE CHANNEL DEEP BRAIN STIMULATOR
9.3.1.3 BATTERY
9.3.1.3.1 RECHARGEABLE
9.3.1.3.2 NON-RECHARGEABLE
9.3.1.4 LEAD
9.3.2 DEEP BRAIN STIMULATION, BY APPLICATION
9.3.2.1 PARKINSON’S DISEASE
9.3.2.2 TREMOR
9.3.2.3 DEPRESSION
9.4 SACRAL NERVE STIMULATION
9.4.1 SACRAL NERVE STIMULATION, BY TYPE
9.4.1.1 BATTERY
9.4.1.2 LEAD
9.5 SACRAL NERVE STIMULATION, BY APPLICATION
9.5.1 URINE INCONTINENCE
9.5.2 FECAL INCONTINENCE
9.6 VAGUS NERVE STIMULATION
9.6.1 VAGUS NERVE STIMULATION, BY TYPE
9.6.1.1 BATTERY
9.6.1.2 LEAD
9.6.2 VAGUS NERVE STIMULATION, BY APPLICATION
9.6.2.1 EPILEPSY
9.6.2.2 OTHERS
9.7 GASTRIC ELECTRICAL STIMULATION
9.7.1 GASTRIC ELECTRICAL STIMULATION, BY TYPE
9.7.1.1 BATTERY
9.7.1.2 LEAD
9.7.2 GASTRIC ELECTRICAL STIMULATION, BY APPLICATION
9.7.2.1 GASTROPARESIS
9.7.2.2 OTHERS
10 NORTH AMERICA INTERNAL NEUROSTIMULATION DEVICES MARKET, BY DISTRIBUTION CHANNEL
10.1 OVERVIEW
10.2 DIRECT TENDER
10.3 THIRD PARTY PROVIDER
11 NORTH AMERICA INTERNAL NEUROSTIMULATION DEVICES MARKET, BY REGION
11.1 NORTH AMERICA
11.1.1 U.S.
11.1.2 CANADA
11.1.3 MEXICO
12 NORTH AMERICA INTERNAL NEUROSTIMULATION DEVICES MARKET: COMPANY LANDSCAPE
12.1 COMPANY SHARE ANALYSIS: NORTH AMERICA
13 SWOT ANALYSIS
14 COMPANY PROFILE
14.1 MEDTRONIC (2021)
14.1.1 COMPANY SNAPSHOT
14.1.2 REVENUE ANALYSIS
14.1.3 COMPANY SHARE ANALYSIS
14.1.4 PRODUCT PORTFOLIO
14.1.5 RECENT DEVELOPMENTS
14.2 BOSTON SCIENTIFIC CORPORATION (2021)
14.2.1 COMPANY SNAPSHOT
14.2.2 REVENUE ANALYSIS
14.2.3 COMPANY SHARE ANALYSIS
14.2.4 PRODUCT PORTFOLIO
14.2.5 RECENT DEVELOPMENTS
14.3 ABBOTT (2021)
14.3.1 COMPANY SNAPSHOT
14.3.2 REVENUE ANALYSIS
14.3.3 COMPANY SHARE ANALYSIS
14.3.4 PRODUCT PORTFOLIO
14.3.5 RECENT DEVELOPMENTS
14.4 LIVANOVA PLC (2021)
14.4.1 COMPANY SNAPSHOT
14.4.2 REVENUE ANALYSIS
14.4.3 COMPANY SHARE ANALYSIS
14.4.4 PRODUCT PORTFOLIO
14.4.5 RECENT DEVELOPMENTS
14.5 NEVRO CORP. (2021)
14.5.1 COMPANY SNAPSHOT
14.5.2 REVENUE ANALYSIS
14.5.3 COMPANY SHARE ANALYSIS
14.5.4 PRODUCT PORTFOLIO
14.5.5 RECENT DEVELOPMENTS
14.6 AXONICS, INC.
14.6.1 COMPANY SNAPSHOT
14.6.2 REVENUE ANALYSIS
14.6.3 PRODUCT PORTFOLIO
14.6.4 RECENT DEVELOPMENTS
14.7 ALEVA NEUROTHERAPEUTICS
14.7.1 COMPANY SNAPSHOT
14.7.2 PRODUCT PORTFOLIO
14.7.3 RECENT DEVELOPMENTS
14.8 BIONIC VISION TECHNOLOGIES.
14.8.1 COMPANY SNAPSHOT
14.8.2 PRODUCT PORTFOLIO
14.8.3 RECENT DEVELOPMENTS
14.9 BLUEWIND MEDICAL
14.9.1 COMPANY SNAPSHOT
14.9.2 PRODUCT PORTFOLIO
14.9.3 RECENT DEVELOPMENTS
14.1 BIOINDUCTION
14.10.1 COMPANY SNAPSHOT
14.10.2 PRODUCT PORTFOLIO
14.10.3 RECENT DEVELOPMENT
14.11 CIRTEC
14.11.1 COMPANY SNAPSHOT
14.11.2 PRODUCT PORTFOLIO
14.11.3 RECENT DEVELOPMENTS
14.12 FINETECH MEDICAL
14.12.1 COMPANY SNAPSHOT
14.12.2 PRODUCT PORTFOLIO
14.12.3 RECENT DEVELOPMENTS
14.13 GIMER MEDICAL
14.13.1 COMPANY SNAPSHOT
14.13.2 PRODUCT PORTFOLIO
14.13.3 RECENT DEVELOPMENTS
14.14 INSPIRE MEDICAL SYSTEMS, INC.
14.14.1 COMPANY SNAPSHOT
14.14.2 REVENUE ANALYSIS
14.14.3 PRODUCT PORTFOLIO
14.14.4 RECENT DEVELOPMENTS
14.15 INTEGER HOLDINGS CORPORATION
14.15.1 COMPANY SNAPSHOT
14.15.2 REVENUE ANALYSIS
14.15.3 PRODUCT PORTFOLIO
14.15.4 RECENT DEVELOPMENT
14.16 INBRAIN NEUROELECTRONICS
14.16.1 COMPANY SNAPSHOT
14.16.2 PRODUCT PORTFOLIO
14.16.3 RECENT DEVELOPMENT
14.17 MAINSTAY MEDICAL
14.17.1 COMPANY SNAPSHOT
14.17.2 REVENUE ANALYSIS
14.17.3 PRODUCT PORTFOLIO
14.17.4 RECENT DEVELOPMENTS
14.18 MICROSEMI (A WHOLLY OWNDED SUBSIDIARY OF MICROCHIP TECHNOLOGY INC.)
14.18.1 COMPANY SNAPSHOT
14.18.2 REVENUE ANALYSIS
14.18.3 PRODUCT PORTFOLIO
14.18.4 RECENT DEVELOPMENTS
14.19 MICROTRANSPONDER INC
14.19.1 COMPANY SNAPSHOT
14.19.2 PRODUCT PORTFOLIO
14.19.3 RECENT DEVELOPMENT
14.2 MICRO-LEADS
14.20.1 COMPANY SNAPSHOT
14.20.2 PRODUCT PORTFOLIO
14.20.3 RECENT DEVELOPMENT
14.21 NALU MEDICAL, INC
14.21.1 COMPANY SNAPSHOT
14.21.2 PRODUCT PORTFOLIO
14.21.3 RECENT DEVELOPMENT
14.22 NEURONANO AB
14.22.1 COMPANY SNAPSHOT
14.22.2 PRODUCT PORTFOLIO
14.22.3 RECENT DEVELOPMENTS
14.23 NEURIMPULSE S.R.L.
14.23.1 COMPANY SNAPSHOT
14.23.2 PRODUCT PORTFOLIO
14.23.3 RECENT DEVELOPMENTS
14.24 NEWRONIKA S.P.A.
14.24.1 COMPANY SNAPSHOT
14.24.2 PRODUCT PORTFOLIO
14.24.3 RECENT DEVELOPMENTS
14.25 OPTOGENTECH GMBH.
14.25.1 COMPANY SNAPSHOT
14.25.2 PRODUCT PORTFOLIO
14.25.3 RECENT DEVELOPMENTS
14.26 ONWARD
14.26.1 COMPANY SNAPSHOT
14.26.2 PRODUCT PORTFOLIO
14.26.3 RECENT DEVELOPMENT
14.27 STIMWAVE LLC (2021)
14.27.1 COMPANY SNAPSHOT
14.27.2 PRODUCT PORTFOLIO
14.27.3 RECENT DEVELOPMENTS
14.28 SEQUANA MEDICAL NV (2021)
14.28.1 COMPANY SNAPSHOT
14.28.2 REVENUE ANALYSIS
14.28.3 PRODUCT PORTFOLIO
14.28.4 RECENT DEVELOPMENTS
14.29 VALENCIA TECHNOLOGIES
14.29.1 COMPANY SNAPSHOT
14.29.2 PRODUCT PORTFOLIO
14.29.3 RECENT DEVELOPMENTS
15 QUESTIONNAIRE
16 RELATED REPORTS
Liste des tableaux
TABLE 1 NORTH AMERICA PREVALENCE OF OBESITY
TABLE 2 NORTH AMERICA INTERNAL NEUROSTIMULATION DEVICES MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 3 NORTH AMERICA SPINAL CORD STIMULATION IN INTERNAL NEUROSTIMULATION DEVICES MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 4 NORTH AMERICA SPINAL CORD STIMULATION IN INTERNAL NEUROSTIMULATION DEVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 5 NORTH AMERICA BATTERY IN INTERNAL NEUROSTIMULATION DEVICES MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 6 NORTH AMERICA BATTERY IN INTERNAL NEUROSTIMULATION DEVICES MARKET, BY PRODUCT TYPE, 2020-2029 (ASP)
TABLE 7 NORTH AMERICA BATTERY IN INTERNAL NEUROSTIMULATION DEVICES MARKET, BY PRODUCT TYPE, 2020-2029 (UNITS)
TABLE 8 NORTH AMERICA LEAD IN INTERNAL NEUROSTIMULATION DEVICES MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 9 NORTH AMERICA LEAD IN INTERNAL NEUROSTIMULATION DEVICES MARKET, BY PRODUCT TYPE, 2020-2029 (ASP)
TABLE 10 NORTH AMERICA LEAD IN INTERNAL NEUROSTIMULATION DEVICES MARKET, BY PRODUCT TYPE, 2020-2029 (UNITS)
TABLE 11 NORTH AMERICA SPINAL CORD STIMULATION IN INTERNAL NEUROSTIMULATION DEVICES MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 12 NORTH AMERICA DEEP BRAIN STIMULATION IN INTERNAL NEUROSTIMULATION DEVICES MARKET, 2020-2029 (USD MILLION)
TABLE 13 NORTH AMERICA DEEP BRAIN STIMULATION IN INTERNAL NEUROSTIMULATION DEVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 14 NORTH AMERICA DEEP BRAIN STIMULATION IN INTERNAL NEUROSTIMULATION DEVICES MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 15 NORTH AMERICA DEEP BRAIN STIMULATION IN INTERNAL NEUROSTIMULATION DEVICES MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 16 NORTH AMERICA BATTERY IN INTERNAL NEUROSTIMULATION DEVICES MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 17 NORTH AMERICA BATTERY IN INTERNAL NEUROSTIMULATION DEVICES MARKET, BY PRODUCT TYPE, 2020-2029 (ASP)
TABLE 18 NORTH AMERICA BATTERY IN INTERNAL NEUROSTIMULATION DEVICES MARKET, BY PRODUCT TYPE, 2020-2029 (UNITS)
TABLE 19 NORTH AMERICA DEEP BRAIN STIMULATION IN INTERNAL NEUROSTIMULATION DEVICES MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 20 NORTH AMERICA SACRAL NERVE STIMULATION IN INTERNAL NEUROSTIMULATION DEVICES MARKET, 2020-2029 (USD MILLION)
TABLE 21 NORTH AMERICA SACRAL NERVE STIMULATION IN INTERNAL NEUROSTIMULATION DEVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 22 NORTH AMERICA SACRAL NERVE STIMULATION IN INTERNAL NEUROSTIMULATION DEVICES MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 23 NORTH AMERICA SACRAL NERVE STIMULATION IN INTERNAL NEUROSTIMULATION DEVICES MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 24 NORTH AMERICA SACRAL NERVE STIMULATION IN INTERNAL NEUROSTIMULATION DEVICES MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 25 NORTH AMERICA VAGUS NERVE STIMULATION IN INTERNAL NEUROSTIMULATION DEVICES MARKET, 2020-2029 (USD MILLION)
TABLE 26 NORTH AMERICA VAGUS NERVE STIMULATION IN INTERNAL NEUROSTIMULATION DEVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 27 NORTH AMERICA VAGUS NERVE STIMULATION IN INTERNAL NEUROSTIMULATION DEVICES MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 28 NORTH AMERICA VAGUS NERVE STIMULATION IN INTERNAL NEUROSTIMULATION DEVICES MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 29 NORTH AMERICA VAGUS NERVE STIMULATION IN INTERNAL NEUROSTIMULATION DEVICES MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 30 NORTH AMERICA GASTRIC ELECTRICAL STIMULATION IN INTERNAL NEUROSTIMULATION DEVICES MARKET, 2020-2029 (USD MILLION)
TABLE 31 NORTH AMERICA GASTRIC ELECTRICAL STIMULATION IN INTERNAL NEUROSTIMULATION DEVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 32 NORTH AMERICA GASTRIC ELECTRICAL STIMULATION IN INTERNAL NEUROSTIMULATION DEVICES MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 33 NORTH AMERICA GASTRIC ELECTRICAL STIMULATION IN INTERNAL NEUROSTIMULATION DEVICES MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 34 NORTH AMERICA GASTRIC ELECTRICAL STIMULATION IN INTERNAL NEUROSTIMULATION DEVICES MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 35 NORTH AMERICA INTERNAL NEUROSTIMULATION DEVICES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 36 NORTH AMERICA DIRECT TENDER IN INTERNAL NEUROSTIMULATION DEVICES MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 37 NORTH AMERICA THIRD PARTY PROVIDER IN INTERNAL NEUROSTIMULATION DEVICES MARKET, 2020-2029 (USD MILLION)
TABLE 38 NORTH AMERICA INTERNAL NEUROSTIMULATION DEVICES MARKET, BY COUNTRY, 2020-2029 (USD MILLION)
TABLE 39 NORTH AMERICA NEUROSTIMULATION DEVICES MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 40 NORTH AMERICA SPINAL CORD STIMULATION IN NEUROSTIMULATION DEVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 41 NORTH AMERICA BATTERY IN NEUROSTIMULATION DEVICES MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 42 NORTH AMERICA BATTERY IN NEUROSTIMULATION DEVICES MARKET, BY PRODUCT TYPE, 2020-2029 (ASP)
TABLE 43 NORTH AMERICA BATTERY IN NEUROSTIMULATION DEVICES MARKET, BY PRODUCT TYPE, 2020-2029 (UNITS)
TABLE 44 NORTH AMERICA LEAD IN NEUROSTIMULATION DEVICES MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 45 NORTH AMERICA LEAD IN NEUROSTIMULATION DEVICES MARKET, BY PRODUCT TYPE, 2020-2029 (ASP)
TABLE 46 NORTH AMERICA LEAD IN NEUROSTIMULATION DEVICES MARKET, BY PRODUCT TYPE, 2020-2029 (UNITS)
TABLE 47 NORTH AMERICA SPINAL CORD STIMULATION IN NEUROSTIMULATION DEVICES MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 48 NORTH AMERICA DEEP BRAIN STIMULATION IN NEUROSTIMULATION DEVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 49 NORTH AMERICA DEEP BRAIN STIMULATION IN NEUROSTIMULATION DEVICES MARKET, BY PRODUCT TYPE, 2020-2029 (ASP)
TABLE 50 NORTH AMERICA DEEP BRAIN STIMULATION IN NEUROSTIMULATION DEVICES MARKET, BY PRODUCT TYPE, 2020-2029 (UNITS)
TABLE 51 NORTH AMERICA BATTERY IN NEUROSTIMULATION DEVICES MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 52 NORTH AMERICA BATTERY IN NEUROSTIMULATION DEVICES MARKET, BY PRODUCT TYPE, 2020-2029 (ASP)
TABLE 53 NORTH AMERICA BATTERY IN NEUROSTIMULATION DEVICES MARKET, BY PRODUCT TYPE, 2020-2029 (UNITS)
TABLE 54 NORTH AMERICA DEEP BRAIN STIMULATION IN NEUROSTIMULATION DEVICES MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 55 NORTH AMERICA SACRAL NERVE STIMULATION IN NEUROSTIMULATION DEVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 56 NORTH AMERICA SACRAL NERVE STIMULATION IN NEUROSTIMULATION DEVICES MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 57 NORTH AMERICA SACRAL NERVE STIMULATION IN NEUROSTIMULATION DEVICES MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 58 NORTH AMERICA SACRAL NERVE STIMULATION IN NEUROSTIMULATION DEVICES MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 59 NORTH AMERICA VAGUS NERVE STIMULATION IN NEUROSTIMULATION DEVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 60 NORTH AMERICA VAGUS NERVE STIMULATION IN NEUROSTIMULATION DEVICES MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 61 NORTH AMERICA VAGUS NERVE STIMULATION IN NEUROSTIMULATION DEVICES MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 62 NORTH AMERICA VAGUS NERVE STIMULATION IN NEUROSTIMULATION DEVICES MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 63 NORTH AMERICA GASTRIC ELECTRICAL STIMULATION IN NEUROSTIMULATION DEVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 64 NORTH AMERICA GASTRIC ELECTRICAL STIMULATION IN NEUROSTIMULATION DEVICES MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 65 NORTH AMERICA GASTRIC ELECTRICAL STIMULATION IN NEUROSTIMULATION DEVICES MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 66 NORTH AMERICA GASTRIC ELECTRICAL STIMULATION IN NEUROSTIMULATION DEVICES MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 67 NORTH AMERICA NEUROSTIMULATION DEVICES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 68 U.S. NEUROSTIMULATION DEVICES MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 69 U.S. SPINAL CORD STIMULATION IN NEUROSTIMULATION DEVICES MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 70 U.S. BATTERY IN NEUROSTIMULATION DEVICES MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 71 U.S. BATTERY IN NEUROSTIMULATION DEVICES MARKET, BY PRODUCT TYPE, 2020-2029 (ASP)
TABLE 72 U.S. BATTERY IN NEUROSTIMULATION DEVICES MARKET, BY PRODUCT TYPE, 2020-2029 (UNITS)
TABLE 73 U.S. LEAD IN NEUROSTIMULATION DEVICES MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 74 U.S. LEAD IN N NEUROSTIMULATION DEVICES MARKET, BY PRODUCT TYPE, 2020-2029 (ASP)
TABLE 75 U.S. LEAD IN NEUROSTIMULATION DEVICES MARKET, BY PRODUCT TYPE, 2020-2029 (UNITS)
TABLE 76 U.S. SPINAL CORD STIMULATION IN NEUROSTIMULATION DEVICES MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 77 U.S. DEEP BRAIN STIMULATION IN NEUROSTIMULATION DEVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 78 U.S. DEEP BRAIN STIMULATION IN NEUROSTIMULATION DEVICES MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 79 U.S. DEEP BRAIN STIMULATION IN NEUROSTIMULATION DEVICES MARKET, BY PRODUCT TYPE, 2020-2029 (UNITS)
TABLE 80 U.S. BATTERY IN NEUROSTIMULATION DEVICES MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 81 U.S. BATTERY IN NEUROSTIMULATION DEVICES MARKET, BY PRODUCT TYPE, 2020-2029 (ASP)
TABLE 82 U.S. BATTERY IN NEUROSTIMULATION DEVICES MARKET, BY PRODUCT TYPE, 2020-2029 (UNITS)
TABLE 83 U.S. DEEP BRAIN STIMULATION IN NEUROSTIMULATION DEVICES MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 84 U.S. SACRAL NERVE STIMULATION IN NEUROSTIMULATION DEVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 85 U.S. SACRAL NERVE STIMULATION IN NEUROSTIMULATION DEVICES MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 86 U.S. SACRAL NERVE STIMULATION IN NEUROSTIMULATION DEVICES MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 87 U.S. SACRAL NERVE STIMULATION IN NEUROSTIMULATION DEVICES MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 88 U.S. VAGUS NERVE STIMULATION IN NEUROSTIMULATION DEVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 89 U.S. VAGUS NERVE STIMULATION IN NEUROSTIMULATION DEVICES MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 90 U.S. VAGUS NERVE STIMULATION IN NEUROSTIMULATION DEVICES MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 91 U.S. VAGUS NERVE STIMULATION IN NEUROSTIMULATION DEVICES MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 92 U.S. GASTRIC ELECTRICAL STIMULATION IN NEUROSTIMULATION DEVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 93 U.S. GASTRIC ELECTRICAL STIMULATION IN NEUROSTIMULATION DEVICES MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 94 U.S. GASTRIC ELECTRICAL STIMULATION IN NEUROSTIMULATION DEVICES MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 95 U.S. GASTRIC ELECTRICAL STIMULATION IN NEUROSTIMULATION DEVICES MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 96 U.S. NEUROSTIMULATION DEVICES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 97 CANADA NEUROSTIMULATION DEVICES MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 98 CANADA SPINAL CORD STIMULATION IN NEUROSTIMULATION DEVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 99 CANADA BATTERY IN NEUROSTIMULATION DEVICES MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 100 CANADA BATTERY IN NEUROSTIMULATION DEVICES MARKET, BY PRODUCT TYPE, 2020-2029 (ASP)
TABLE 101 CANADA BATTERY IN NEUROSTIMULATION DEVICES MARKET, BY PRODUCT TYPE, 2020-2029 (UNITS)
TABLE 102 CANADA LEAD IN NEUROSTIMULATION DEVICES MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 103 CANADA LEAD IN NEUROSTIMULATION DEVICES MARKET, BY PRODUCT TYPE, 2020-2029 (ASP)
TABLE 104 CANADA LEAD IN NEUROSTIMULATION DEVICES MARKET, BY PRODUCT TYPE, 2020-2029 (UNITS)
TABLE 105 CANADA SPINAL CORD STIMULATION IN NEUROSTIMULATION DEVICES MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 106 CANADA DEEP BRAIN STIMULATION IN NEUROSTIMULATION DEVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 107 CANADA DEEP BRAIN STIMULATION IN NEUROSTIMULATION DEVICES MARKET, BY PRODUCT TYPE, 2020-2029 (ASP)
TABLE 108 CANADA DEEP BRAIN STIMULATION IN NEUROSTIMULATION DEVICES MARKET, BY PRODUCT TYPE, 2020-2029 (UNITS)
TABLE 109 CANADA BATTERY IN NEUROSTIMULATION DEVICES MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 110 CANADA BATTERY IN NEUROSTIMULATION DEVICES MARKET, BY PRODUCT TYPE, 2020-2029 (ASP)
TABLE 111 CANADA BATTERY IN NEUROSTIMULATION DEVICES MARKET, BY PRODUCT TYPE, 2020-2029 (UNITS)
TABLE 112 CANADA DEEP BRAIN STIMULATION IN NEUROSTIMULATION DEVICES MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 113 CANADA SACRAL NERVE STIMULATION IN NEUROSTIMULATION DEVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 114 CANADA SACRAL NERVE STIMULATION IN NEUROSTIMULATION DEVICES MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 115 CANADA SACRAL NERVE STIMULATION IN NEUROSTIMULATION DEVICES MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 116 CANADA SACRAL NERVE STIMULATION IN NEUROSTIMULATION DEVICES MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 117 CANADA VAGUS NERVE STIMULATION IN NEUROSTIMULATION DEVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 118 CANADA VAGUS NERVE STIMULATION IN NEUROSTIMULATION DEVICES MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 119 CANADA VAGUS NERVE STIMULATION IN NEUROSTIMULATION DEVICES MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 120 CANADA VAGUS NERVE STIMULATION IN NEUROSTIMULATION DEVICES MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 121 CANADA GASTRIC ELECTRICAL STIMULATION IN NEUROSTIMULATION DEVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 122 CANADA GASTRIC ELECTRICAL STIMULATION IN NEUROSTIMULATION DEVICES MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 123 CANADA GASTRIC ELECTRICAL STIMULATION IN NEUROSTIMULATION DEVICES MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 124 CANADA GASTRIC ELECTRICAL STIMULATION IN NEUROSTIMULATION DEVICES MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 125 CANADA NEUROSTIMULATION DEVICES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 126 MEXICO NEUROSTIMULATION DEVICES MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 127 MEXICO SPINAL CORD STIMULATION IN NEUROSTIMULATION DEVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 128 MEXICO BATTERY IN NEUROSTIMULATION DEVICES MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 129 MEXICO BATTERY IN NEUROSTIMULATION DEVICES MARKET, BY PRODUCT TYPE, 2020-2029 (ASP)
TABLE 130 MEXICO BATTERY IN NEUROSTIMULATION DEVICES MARKET, BY PRODUCT TYPE, 2020-2029 (UNITS)
TABLE 131 MEXICO LEAD IN NEUROSTIMULATION DEVICES MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 132 MEXICO LEAD IN NEUROSTIMULATION DEVICES MARKET, BY PRODUCT TYPE, 2020-2029 (ASP)
TABLE 133 MEXICO LEAD IN NEUROSTIMULATION DEVICES MARKET, BY PRODUCT TYPE, 2020-2029 (UNITS)
TABLE 134 MEXICO SPINAL CORD STIMULATION IN NEUROSTIMULATION DEVICES MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 135 MEXICO DEEP BRAIN STIMULATION IN NEUROSTIMULATION DEVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 136 MEXICO DEEP BRAIN STIMULATION IN NEUROSTIMULATION DEVICES MARKET, BY PRODUCT TYPE, 2020-2029 (ASP)
TABLE 137 MEXICO DEEP BRAIN STIMULATION IN NEUROSTIMULATION DEVICES MARKET, BY PRODUCT TYPE, 2020-2029 (UNITS)
TABLE 138 MEXICO BATTERY IN NEUROSTIMULATION DEVICES MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 139 MEXICO BATTERY IN NEUROSTIMULATION DEVICES MARKET, BY PRODUCT TYPE, 2020-2029 (ASP)
TABLE 140 MEXICO BATTERY IN NEUROSTIMULATION DEVICES MARKET, BY PRODUCT TYPE, 2020-2029 (UNITS)
TABLE 141 MEXICO DEEP BRAIN STIMULATION IN NEUROSTIMULATION DEVICES MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 142 MEXICO SACRAL NERVE STIMULATION IN NEUROSTIMULATION DEVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 143 MEXICO SACRAL NERVE STIMULATION IN NEUROSTIMULATION DEVICES MARKET, BY PRODUCT TYPE, 2020-2029 (ASP)
TABLE 144 MEXICO SACRAL NERVE STIMULATION IN NEUROSTIMULATION DEVICES MARKET, BY PRODUCT TYPE, 2020-2029 (UNITS)
TABLE 145 MEXICO SACRAL NERVE STIMULATION IN NEUROSTIMULATION DEVICES MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 146 MEXICO VAGUS NERVE STIMULATION IN NEUROSTIMULATION DEVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 147 MEXICO VAGUS NERVE STIMULATION IN NEUROSTIMULATION DEVICES MARKET, BY PRODUCT TYPE, 2020-2029 (ASP)
TABLE 148 MEXICO VAGUS NERVE STIMULATION IN NEUROSTIMULATION DEVICES MARKET, BY PRODUCT TYPE, 2020-2029 (UNITS)
TABLE 149 MEXICO VAGUS NERVE STIMULATION IN NEUROSTIMULATION DEVICES MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 150 MEXICO GASTRIC ELECTRICAL STIMULATION IN NEUROSTIMULATION DEVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 151 MEXICO GASTRIC ELECTRICAL STIMULATION IN NEUROSTIMULATION DEVICES MARKET, BY PRODUCT TYPE, 2020-2029 (ASP)
TABLE 152 MEXICO GASTRIC ELECTRICAL STIMULATION IN NEUROSTIMULATION DEVICES MARKET, BY PRODUCT TYPE, 2020-2029 (UNITS)
TABLE 153 MEXICO GASTRIC ELECTRICAL STIMULATION IN NEUROSTIMULATION DEVICES MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 154 MEXICO NEUROSTIMULATION DEVICES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
Liste des figures
FIGURE 1 NORTH AMERICA INTERNAL NEUROSTIMULATION DEVICES MARKET: SEGMENTATION
FIGURE 2 NORTH AMERICA INTERNAL NEUROSTIMULATION DEVICES MARKET: GEOGRAPHIC SCOPE
FIGURE 3 NORTH AMERICA INTERNAL NEUROSTIMULATION DEVICES MARKET: DATA TRIANGULATION
FIGURE 4 NORTH AMERICA INTERNAL NEUROSTIMULATION DEVICES MARKET: SNAPSHOT
FIGURE 5 NORTH AMERICA INTERNAL NEUROSTIMULATION DEVICES MARKET: BOTTOM UP APPROACH
FIGURE 6 NORTH AMERICA INTERNAL NEUROSTIMULATION DEVICES MARKET: TOP DOWN APPROACH
FIGURE 7 NORTH AMERICA INTERNAL NEUROSTIMULATION DEVICES MARKET: INTERVIEWS BY REGION AND DESIGNATION
FIGURE 8 NORTH AMERICA INTERNAL NEUROSTIMULATION DEVICES MARKET: DBMR MARKET POSITION GRID
FIGURE 9 NORTH AMERICA INTERNAL NEUROSTIMULATION DEVICES MARKET: THE CATEGORY VS TIME GRID
FIGURE 10 NORTH AMERICA INTERNAL NEUROSTIMULATION DEVICES MARKET SEGMENTATION
FIGURE 11 INCREASE IN PREVALENCE AND INCIDENCE OF NEUROLOGICAL DISEASES AND DEMAND FOR INTERNAL NEUROSTIMULATION DEVICES AS A ADD ON THERAPY ARE EXPECTED TO DRIVE THE NORTH AMERICA INTERNAL NEUROSTIMULATIOJ DEVICES MARKET IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 12 SPINAL CORD STIMULATION IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA INTERNAL NEUROSTIMULATION DEVICES MARKET IN 2022 TO 2029
FIGURE 13 NORTH AMERICA INCIDENCE OF ISCHEMIA
FIGURE 14 NORTH AMERICA INCIDENCE OF PARKINSON'S DISEASES
FIGURE 15 NORTH AMERICA INCIDENCE OF TREMOR
FIGURE 16 NORTH AMERICA INCIDENCE RATE OF EPILEPSY
FIGURE 17 NORTH AMERICA INCIDENCE RATE OF GASTROPARESIS
FIGURE 18 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE NORTH AMERICA INTERNAL NEUROSTIMULATION DEVICES MARKET
FIGURE 19 INCIDENCE OF ADULT ONSET BRAIN DISORDERS IN THE U.S. IN 2021
FIGURE 20 NORTH AMERICA INTERNAL NEUROSTIMULATION DEVICES MARKET: BY PRODUCT TYPE, 2021
FIGURE 21 NORTH AMERICA INTERNAL NEUROSTIMULATION DEVICES MARKET: BY PRODUCT TYPE, 2022-2029 (USD MILLION)
FIGURE 22 NORTH AMERICA INTERNAL NEUROSTIMULATION DEVICES MARKET: BY PRODUCT TYPE, CAGR (2022-2029)
FIGURE 23 NORTH AMERICA INTERNAL NEUROSTIMULATION DEVICES MARKET: BY PRODUCT TYPE, LIFELINE CURVE
FIGURE 24 NORTH AMERICA INTERNAL NEUROSTIMULATION DEVICES MARKET: BY DISTRIBUTION CHANNEL, 2021
FIGURE 25 NORTH AMERICA INTERNAL NEUROSTIMULATION DEVICES MARKET: BY DISTRIBUTION CHANNEL, 2022-2029 (USD MILLION)
FIGURE 26 NORTH AMERICA INTERNAL NEUROSTIMULATION DEVICES MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029)
FIGURE 27 NORTH AMERICA INTERNAL NEUROSTIMULATION DEVICES MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 28 NORTH AMERICA INTERNAL NEUROSTIMULATION DEVICES MARKET: SNAPSHOT (2021)
FIGURE 29 NORTH AMERICA INTERNAL NEUROSTIMULATION DEVICES MARKET: BY COUNTRY (2021)
FIGURE 30 NORTH AMERICA INTERNAL NEUROSTIMULATION DEVICES MARKET: BY COUNTRY (2022 & 2029)
FIGURE 31 NORTH AMERICA INTERNAL NEUROSTIMULATION DEVICES MARKET: BY COUNTRY (2021 & 2029)
FIGURE 32 NORTH AMERICA INTERNAL NEUROSTIMULATION DEVICES MARKET: BY PRODUCT TYPE (2022-2029)
FIGURE 33 NORTH AMERICA INTERNAL NEUROSTIMULATION DEVICES MARKET: COMPANY SHARE 2021 (%)
Méthodologie de recherche
La collecte de données et l'analyse de l'année de base sont effectuées à l'aide de modules de collecte de données avec des échantillons de grande taille. L'étape consiste à obtenir des informations sur le marché ou des données connexes via diverses sources et stratégies. Elle comprend l'examen et la planification à l'avance de toutes les données acquises dans le passé. Elle englobe également l'examen des incohérences d'informations observées dans différentes sources d'informations. Les données de marché sont analysées et estimées à l'aide de modèles statistiques et cohérents de marché. De plus, l'analyse des parts de marché et l'analyse des tendances clés sont les principaux facteurs de succès du rapport de marché. Pour en savoir plus, veuillez demander un appel d'analyste ou déposer votre demande.
La méthodologie de recherche clé utilisée par l'équipe de recherche DBMR est la triangulation des données qui implique l'exploration de données, l'analyse de l'impact des variables de données sur le marché et la validation primaire (expert du secteur). Les modèles de données incluent la grille de positionnement des fournisseurs, l'analyse de la chronologie du marché, l'aperçu et le guide du marché, la grille de positionnement des entreprises, l'analyse des brevets, l'analyse des prix, l'analyse des parts de marché des entreprises, les normes de mesure, l'analyse globale par rapport à l'analyse régionale et des parts des fournisseurs. Pour en savoir plus sur la méthodologie de recherche, envoyez une demande pour parler à nos experts du secteur.
Personnalisation disponible
Data Bridge Market Research est un leader de la recherche formative avancée. Nous sommes fiers de fournir à nos clients existants et nouveaux des données et des analyses qui correspondent à leurs objectifs. Le rapport peut être personnalisé pour inclure une analyse des tendances des prix des marques cibles, une compréhension du marché pour d'autres pays (demandez la liste des pays), des données sur les résultats des essais cliniques, une revue de la littérature, une analyse du marché des produits remis à neuf et de la base de produits. L'analyse du marché des concurrents cibles peut être analysée à partir d'une analyse basée sur la technologie jusqu'à des stratégies de portefeuille de marché. Nous pouvons ajouter autant de concurrents que vous le souhaitez, dans le format et le style de données que vous recherchez. Notre équipe d'analystes peut également vous fournir des données sous forme de fichiers Excel bruts, de tableaux croisés dynamiques (Fact book) ou peut vous aider à créer des présentations à partir des ensembles de données disponibles dans le rapport.
